Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Monitoreo remoto del embarazo para mejorar el acceso (REACTIVE)

19 de octubre de 2026 actualizado por: Samuel Parry, MD, University of Pennsylvania

Monitoreo remoto del embarazo para mejorar el acceso: el ensayo REACTIVE

The goal of this clinical trial is to determine the effectiveness of remote nonstress test (NST) compared to in-clinic NSTs in improving fetal testing completion rates. Participants will be randomized to either in-clinic NSTs or use of an FDA-approved remote monitoring belt for their pregnancy monitoring.

Descripción general del estudio

Estado

Terminado

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Actual)

400

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Singleton pregnancy
  • Gestational age between 30 weeks 0 days and 35 weeks 6 days
  • Pregnant patients who have clinical indication for fetal surveillance with NSTs (based on UPHS Health System clinical guidelines for antenatal monitoring)
  • Able to provide written consent
  • English speaking

Exclusion Criteria:

  • Multiple gestations
  • Maternal pre-gravid BMI greater than 45kg/m2
  • Presence of an implanted pacemaker or defibrillator
  • Active abdominal skin infection
  • A known amniotic fluid index (AFI) less than 5cm or greater than 25cm on the most recent ultrasound (if available) prior to randomization
  • Delivery is planned within 2 weeks of potential randomization

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: NST remoto

INVU monitoring belt used for remote NSTs

Comparador activo: NST en la clínica - Estándar de atención

In-clinic NSTs - standard of care

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fetal Testing Completion Rate
Periodo de tiempo: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Percentage of recommended antenatal testing sessions successfully completed, defined as a clinically interpreted test performed. Calculated for each participant as: number of NST visits completed divided by number of NST visits expected × 100.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Fetal Testing Completion Rate in Black Versus Non-Black Subjects
Periodo de tiempo: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Comparison between Black and non-Black subjects' percentage of recommended antenatal testing sessions that were successfully completed as defined as a clinically interpreted test was performed. Calculated as the number of NST visits completed divided by the number of NST visits expected per participant × 100.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fetal Monitoring Outcomes: Number of Visits to the Antenatal Testing Unit
Periodo de tiempo: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Count of visits to the office for in-person monitoring

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Fetal Monitoring Outcomes: Percentage of Non-Stress Test Sessions Requiring Provider-Recommended Prolonged Monitoring
Periodo de tiempo: From randomization until delivery.

For each participant, the percentage of all NST sessions requiring prolonged monitoring (>40 minutes) was calculated. The median participant-level percentage is reported.

From randomization until delivery.
Fetal Monitoring Outcomes: Average Duration of Non-Stress Test Monitoring Sessions
Periodo de tiempo: From randomization until delivery.

Mean duration of NST monitoring sessions across all NSTs completed by each participant from randomization to delivery. Participant-level means were calculated and summarized by study arm.

From randomization until delivery.
Fetal Monitoring Outcomes: Non-reactive NST Rate
Periodo de tiempo: From randomization until delivery

Percentage of NSTs that were non-reactive among all NSTs completed for each participant.

From randomization until delivery
Fetal Monitoring Outcomes: Percentage of NSTs Resulting in Biophysical Profile Evaluation
Periodo de tiempo: From randomization until delivery.

Percentage of completed NSTs followed by biophysical profile assessment.

From randomization until delivery.
Fetal Monitoring Outcomes: Number of Participants With ≥1 Obstetrical Triage Visit
Periodo de tiempo: From randomization to delivery

Number of Participants With ≥1 Obstetrical Triage Visit

From randomization to delivery
Fetal Monitoring Outcomes: Number of Participants Who Had Any Triage Visit Directly Related to a Fetal Monitoring Visit
Periodo de tiempo: From randomization to delivery

Number of participants who underwent at least one obstetrical triage evaluation directly related to a fetal monitoring visit, during the study period from randomization until delivery.

From randomization to delivery
Fetal Monitoring Outcomes: Number of Participants Recommended for Delivery Based on Findings on Fetal Monitoring Result
Periodo de tiempo: From randomization to delivery

Count of the number of subjects in each arm who receive a recommendation for delivery based on the findings of the fetal monitoring results.

From randomization to delivery
Fetal Monitoring Outcomes: Percentage of NSTs Not Completed Within the Prescribed Window
Periodo de tiempo: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Percentage of NSTs which occur outside of prescribed window, for example, if a weekly testing regimen is prescribed, an appointment 8 or more days following the last one would count as 1 missed calendar window.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Obstetrics Outcomes: Gestational Age at Delivery
Periodo de tiempo: time of delivery

gestational age at time of delivery

time of delivery
Obstetrics Outcomes: Number of Participants With Preterm Delivery
Periodo de tiempo: time of delivery

preterm delivery is defined as less than 37 weeks gestational age

time of delivery
Obstetrics Outcomes: Mode of Delivery
Periodo de tiempo: time of delivery

categorized as vaginal or cesarean

time of delivery
Obstetrics Outcomes: Number of Participants With an Indication for Labor Induction
Periodo de tiempo: time of labor induction

in subjects who have labor induction, indication for inducing labor

time of labor induction
Obstetrics Outcomes: Number of Participants With an Indication for Cesarean Section
Periodo de tiempo: time of delivery

in subjects who have a cesarean section delivery, indication for cesarean section

time of delivery
Obstetrics Outcomes: Number of Participants With Composite Neonatal Morbidity
Periodo de tiempo: from delivery to 6 weeks post-delivery

Number of participants whose neonate experienced at least one component of the composite neonatal morbidity outcome, defined as severe respiratory distress, neonatal resuscitation outside the delivery room, or neonatal death.

from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Neonatal Cord Blood pH
Periodo de tiempo: time of delivery
time of delivery
Obstetrics Outcomes: Apgar Scores
Periodo de tiempo: one and five minutes after delivery

Apgar score at 1 and 5 minutes after delivery. Scores range from 0 to 10, with higher scores indicating better neonatal condition

one and five minutes after delivery
Obstetrics Outcomes: Number of Participants With an Admission to the Neonatal Intensive Care Unit
Periodo de tiempo: from delivery to 6 weeks post-delivery
from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Number of Participants Who Had an Admission to the Neonatal Intensive Care Unit for Greater Than 48 Hours
Periodo de tiempo: from delivery to 6 weeks post-delivery
from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Maternal Length of Hospital Stay
Periodo de tiempo: Delivery hospitalization

Length of maternal hospitalization associated with the delivery admission, measured from hospital admission for delivery through maternal discharge.

Delivery hospitalization
Obstetrics Outcomes: Neonatal Length of Hospital Stay
Periodo de tiempo: Birth hospitalization

Length of neonatal hospitalization from birth through hospital discharge.

Birth hospitalization
Cost-effectiveness Outcomes: Productivity Loss Due to Antenatal Testing and Monitoring
Periodo de tiempo: From randomization until delivery (approximately 10 weeks on average)

Productivity loss was assessed by summing the number of days of work missed reported by participants across the two study productivity assessments. The reported value represents the total number of work days missed during the study period for each participant.

From randomization until delivery (approximately 10 weeks on average)
Cost-effectiveness Outcomes: Total Societal Perspective Cost
Periodo de tiempo: Randomization through delivery

Total societal perspective cost per participant, calculated as the sum of direct healthcare costs, informal healthcare costs, and productivity costs incurred from randomization through delivery. Costs are reported in U.S. dollars (USD). The societal perspective includes costs related to antenatal testing, delivery hospitalization, neonatal care, triage visits, antepartum admissions, productivity losses, caregiving, and transportation.

Randomization through delivery
Implementation Outcomes: Theory-informed Acceptability Questionnaire
Periodo de tiempo: at time of delivery

Participant acceptability of the assigned fetal monitoring strategy was assessed using an 8-item Theory-Informed Acceptability Questionnaire (TFA). Total scores range from 8 to 40, with higher scores indicating greater acceptability of the monitoring approach.

at time of delivery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de mayo de 2023

Finalización primaria (Actual)

26 de septiembre de 2025

Finalización del estudio (Actual)

26 de septiembre de 2025

Fechas de registro del estudio

Enviado por primera vez

27 de abril de 2023

Primero enviado que cumplió con los criterios de control de calidad

27 de abril de 2023

Publicado por primera vez (Actual)

8 de mayo de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir